文献速递血栓与止血

调控CD38胞外酶活性经去乙酰化酶Sirt-1恢复免疫性血小板减少症中调节性T细胞功能

Manipulating CD38 ectoenzymatic activity revitalizes regulatory T cells via deacetylase Sirt-1 in immune thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2026-06-26

本研究探讨CD38靶向治疗对免疫性血小板减少症(ITP)患者调节性T细胞(Tregs)功能重编程的影响及Sirt-1相关分子机制。通过患者样本和活动性ITP小鼠模型进行Sirt-1或Treg清除干预,结合流式细胞术免疫表型分析和转录组分析。结果显示达雷妥尤单抗通过阻断Sirt-1促进ITP患者Tregs扩增并增强其抑制活性,抗CD38治疗升高Tregs整体乙酰化水平和细胞内NAD+水平,改善ITP小鼠免疫格局并缓解血小板减少。

要点

  • 达雷妥尤单抗通过阻断Sirt-1促进ITP患者Tregs扩增并增强抑制活性
  • 抗CD38治疗升高Tregs整体乙酰化和细胞内NAD+水平
  • 清除Tregs证实Sirt诱导的重编程对Tregs具有特异性

核心结论

  • 调控CD38胞外酶活性可能通过Sirt-1恢复免疫平衡,为ITP提供新靶点并解释其长期疗效。

研究设计与样本

  • 研究纳入ITP患者样本和活动性ITP小鼠模型,进行Sirt-1或Treg清除干预,采用流式细胞术免疫表型分析和转录组分析。

主要发现

  • 达雷妥尤单抗通过阻断Sirt-1促进ITP患者Tregs扩增并增强其抑制活性。
  • 抗CD38治疗升高Tregs整体乙酰化水平和细胞内NAD+水平,并改善ITP小鼠免疫格局、缓解血小板减少。
  • 治疗后小鼠Tregs转录组分析揭示表观遗传通路改变及CBX3作为Sirt-1调节因子。
  • 清除Tregs证实Sirt诱导的重编程对Tregs具有特异性。

临床怎么用

  • CD38靶向治疗可能通过Sirt-1依赖机制恢复ITP患者免疫耐受,支持其长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune thrombocytopenia (ITP) is the most common acquired bleeding disorder where considerable dysfunction of regulatory T cells (Tregs) contributes to the loss of immune tolerance. CD38 is a transmembrane glycoprotein equipped with ectoenzymatic activities. It affects other NAD+-consuming enzymes such as deacetylase Sirtuin-1 (Sirt-1), which is pivotal for Treg stability. Anti-CD38 monoclonal antibodies exert ectoenzyme-modulating capacity and has been proven to rapidly boost and maintain platelet levels in patients with ITP. OBJECTIVES: This study aimed to investigate the effect of CD38-targeted therapy on the functional reprogramming of Tregs in patients with ITP, including its molecular mechanisms associated with Sirt-1 in vitro and in vivo. METHODS: Patient samples and a murine model of active ITP were subject to multiple interventions of Sirt-1 or Treg depletion, followed by integrative immunophenotyping by flow cytometry and transcriptome profiling. Here, anti-CD38 therapies were credited for an equally important mechanism to the depletion of plasma cells in autoimmune diseases. RESULTS: Daratumumab promoted expansion of and enhanced the suppressive activity of Tregs from patients with ITP by blocking Sirt-1. Anti-CD38 therapy elevated global acetylation and intracellular NAD+ levels in Tregs and modified the immune landscape apart from alleviating thrombocytopenia in ITP mice. Transcriptome profiling of posttreatment murine Tregs elucidated altered epigenetic pathways and CBX3 as a Sirt-1 regulator. Depleting Tregs finally confirmed that Sirt-induced reprogramming was specific for Tregs. CONCLUSION: This study suggests that manipulating the ectoenzymatic activity of CD38 holds potential to restore immune balance via Sirt-1, providing a novel target and rationalizing its long-term efficacy in patients with ITP.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Zhu M, Wang H, Xu Y, et al. Manipulating CD38 ectoenzymatic activity revitalizes regulatory T cells via deacetylase Sirt-1 in immune thrombocytopenia. J Thromb Haemost. 2026. PMID: 42362030. doi:10.1016/j.jtha.2026.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。